T1	Outcomes 663 767	European Organisation for Research and Treatment of Cancer Quality of Life (EORTC QOL)-C30 questionnaire
T2	Outcomes 843 936	(pain, anorexia, diarrhoea, fatigue, nausea and vomiting, dyspnea, constipation and insomnia)
T3	Outcomes 1142 1168	median time to progression
T4	Outcomes 1343 1358	median survival
T5	Outcomes 1583 1591	efficacy
T6	Outcomes 1596 1604	survival
T7	Outcomes 1654 1678	haematological toxicity.
T8	Outcomes 1679 1706	Non-haematological toxicity
